Daewoong Pharmaceutical Overview
- Year Founded
-
1945
- Status
-
Public
- Employees
-
1,777
- Stock Symbol
-
069620
- Investments
-
41
- Share Price
-
$76.36
- (As of Friday Closing)
Daewoong Pharmaceutical General Information
Description
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
Contact Information
Website
www.daewoong.co.krCorporate Office
- Bongeunsa-ro 114-gil 12
- Seoul, Gangnam
- South Korea
Corporate Office
- Bongeunsa-ro 114-gil 12
- Seoul, Gangnam
- South Korea
Daewoong Pharmaceutical Stock Performance
As of 13-Nov-2026, Daewoong Pharmaceutical’s stock price is $76.36. Its current market cap is $879M with 11.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $76.36 | $76.68 | $67.87 - $137.07 | $879M | 11.5M | 20.2K | $11.71 |
Daewoong Pharmaceutical Financials Summary
As of 30-Jun-2026, Daewoong Pharmaceutical has a trailing 12-month revenue of $1.13B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,398,160 | 1,871,731 | 1,404,004 | 1,338,644 |
| Revenue | 1,126,759 | 1,103,823 | 1,042,689 | 1,051,917 |
| EBITDA | 178,001 | 177,625 | 78,730 | 134,842 |
| Net Income | 134,692 | 137,622 | 18,128 | 93,112 |
| Total Assets | 1,644,560 | 1,640,822 | 1,342,170 | 1,373,740 |
| Total Debt | 599,489 | 575,962 | 440,775 | 342,420 |
Daewoong Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Daewoong Pharmaceutical Comparisons
Industry
Financing
Details
Daewoong Pharmaceutical Competitors (8)
One of Daewoong Pharmaceutical’s 8 competitors is Lilly USA, a Corporation company based in Indianapolis, IN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lilly USA | Corporation | Indianapolis, IN | ||||
| Hoechst Pakistan | Corporate Backed or Acquired | Karachi, Pakistan | ||||
| Celltrion | Formerly VC-backed | Incheon, South Korea | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Dr. Reddy's | Corporation | Hyderabad, India |
Daewoong Pharmaceutical Patents
Daewoong Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026235345-A1 | Pharmaceutical composition for preventing or treating metabolic dysfunction-associated steatotic liver disease, comprising enavogliflozin as active ingredient | Pending | 08-May-2025 | ||
| WO-2026230955-A1 | Pharmaceutical composition for preventing or treating hydrocephalus or ventriculomegaly due to periventricular ciliary dysfunction comprising enavogliflozin | Pending | 30-Apr-2025 | ||
| WO-2026225879-A1 | Pharmaceutical composition for preventing or treating cancer or tumors | Pending | 25-Apr-2025 | ||
| WO-2026221464-A1 | Sustained release pharmaceutical formulation comprising ropivacaine and preparation method thereof | Pending | 17-Apr-2025 | ||
| WO-2026216985-A1 | Crystalline form of 2'-chloro-n-(6-(cyclopropylethynyl)thiazolo[4,5-b]pyrazin-2-yl)-5'-methoxy-6-methyl-4,4'-bipyridine-3-carboxamide | Pending | 10-Apr-2025 |
Daewoong Pharmaceutical Signals
Daewoong Pharmaceutical Investments & Acquisitions (41)
Daewoong Pharmaceutical’s most recent deal was a Early Stage VC with Hurotics for . The deal was made on 15-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hurotics | 15-Oct-2026 | Early Stage VC | Therapeutic Devices | ||
| Puzzle AI | 27-Aug-2026 | Later Stage VC | Medical Records Systems | ||
| EXOSYSTEMS | 28-Jun-2026 | Later Stage VC | Diagnostic Equipment | ||
| PROMEDIUS | 05-Jun-2026 | Later Stage VC | Decision/Risk Analysis | ||
| Turn Biotechnologies | 21-May-2026 | Merger/Acquisition | Drug Discovery |
Daewoong Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 05, 2026
29.77 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Daewoong Pharmaceutical Exits (6)
Daewoong Pharmaceutical’s most recent exit was on 29-Jul-2022 from AEON Biopharma. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| AEON Biopharma | 29-Jul-2022 | Completed |
|
||
| Seers (Monitoring Equipment) | 14-May-2022 | Completed |
|
||
| Oncocross | 01-Mar-2021 | Completed |
|
||
| Inventage Lab | 01-Jan-2020 | Completed |
|
||
| Parataxis Korea | 01-Apr-2019 | Later Stage VC | Completed |
|
Daewoong Pharmaceutical Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Daewoong Investment | Seoul, South Korea | 2023 | |
| CGBio | Seoul, South Korea | 2006 | |
| Liaoning Daewoong Pharmaceutical | Benxi, China |
Daewoong Pharmaceutical FAQs
-
When was Daewoong Pharmaceutical founded?
Daewoong Pharmaceutical was founded in 1945.
-
Where is Daewoong Pharmaceutical headquartered?
Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
-
What is the size of Daewoong Pharmaceutical?
Daewoong Pharmaceutical has 1,777 total employees.
-
What industry is Daewoong Pharmaceutical in?
Daewoong Pharmaceutical’s primary industry is Drug Discovery.
-
Is Daewoong Pharmaceutical a private or public company?
Daewoong Pharmaceutical is a Public company.
-
What is Daewoong Pharmaceutical’s stock symbol?
The ticker symbol for Daewoong Pharmaceutical is 069620.
-
What is the current stock price of Daewoong Pharmaceutical?
As of 13-Nov-2026 the stock price of Daewoong Pharmaceutical is $76.36.
-
What is the current market cap of Daewoong Pharmaceutical?
The current market capitalization of Daewoong Pharmaceutical is $879M.
-
What is Daewoong Pharmaceutical’s current revenue?
The trailing twelve month revenue for Daewoong Pharmaceutical is $1.13B.
-
Who are Daewoong Pharmaceutical’s competitors?
Lilly USA, Hoechst Pakistan, Celltrion, GSK, and Dr. Reddy's are some of the 8 competitors of Daewoong Pharmaceutical.
-
What is Daewoong Pharmaceutical’s annual earnings per share (EPS)?
Daewoong Pharmaceutical’s EPS for 12 months was $11.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process